埃罗替尼对肾上腺皮质癌SW13细胞系增殖及凋亡的影响及其机制研究  

The effect of EGFR inhibitor Erlotinib on the proliferation and apoptosis of adrenocarcinoma SW13 cell line

作　　者：徐烈雨 廉建坡 陈东宁[1] 祝宇[1] 赵菊平[1] 吴瑜璇[1] 沈周俊[1] 宁光[2] 

机构地区：[1]上海交通大学医学院附属瑞金医院泌尿外科,上海200025 [2]上海交通大学医学院附属瑞金医院内分泌科,上海200025

出　　处：《现代泌尿外科杂志》2015年第11期808-812,共5页Journal of Modern Urology

基　　金：国家自然科学基金(No.81272936);上海市科委引导基金(No.134119a2700)

摘　　要：目的体外探讨EGFR抑制剂埃罗替尼(Erlotinib)对肾上腺皮质癌SW13细胞的增殖、凋亡及细胞周期的影响。方法应用MTT试验观察埃罗替尼对SW13细胞系的生长抑制作用;流式细胞实验检测其对肾上腺皮质癌细胞系凋亡及细胞周期的影响;Western blot检测埃罗替尼对EGFR下游信号通路蛋白的影响,进一步阐明其作用机制。结果埃罗替尼呈剂量-时间相关地抑制SW13细胞增殖,药物作用24h时IC50为20.51μmol/L;埃罗替尼可以诱导SW13细胞凋亡,处理24h后,空白组早期凋亡率为(1.62±0.21)%,20μmol/L埃罗替尼治疗组为(13.49±0.48)%,存在统计学差异(P<0.05);而埃罗替尼对SW13细胞周期分布无影响。埃罗替尼下调p-ERK蛋白表达水平,但不影响p-mTOR表达水平。结论埃罗替尼可以抑制SW13细胞增殖,其作用机制可能与促进凋亡、抑制ERK信号通路有关。Objective To investigate the effect and mechanism of epidermal growth factor receptor （EGFR） inhibitor Erlotinib on human adrenocortical carcinoma cell line SW13 in vitro. Methods The proliferation of SW13 after exposure to Erlotinib was detected with MTT assay. The apoptosis and cell cycle was determined with Annex-VI and flow cytometry. The expression of proteins associated with EGFR signaling were examined with Western blot. Results Erlotinib inhibited SWl3 cell proliferation in a dose- and time- dependent manner in vitro. The IC50 after exposure of 24 h was 20.51 μmol/L. Erlotinib induced apoptosis, cell apoptosis rate in erlotinib 20μmol/L group 24 h was （13.49±0.48）%, significantly higher than that in the control group （1.62±0.21）%. Erlotinib had no effect on cell cycle. The expression of p-ERK was down regulated, while the expression of p-mTOR was not affected. Conclusions The proliferation of SW13 cells could be inhibited by Erlotinib, and possible mechanisms involved up-regulated apoptosis and down-regulated ERK signaling pathway.

关 键 词：表皮生长因子受体 埃罗替尼 肾上腺皮质癌 增殖 凋亡 

分 类 号：R736.6[医药卫生—肿瘤]